These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic? Kim D; Paik JH; Shin DW; Kim HS; Park CS; Kang JH Exp Neurobiol; 2014 Dec; 23(4):352-64. PubMed ID: 25548535 [TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803 [TBL] [Abstract][Full Text] [Related]
29. Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Farah R; Haraty H; Salame Z; Fares Y; Ojcius DM; Said Sadier N Biomed J; 2018 Apr; 41(2):63-87. PubMed ID: 29866603 [TBL] [Abstract][Full Text] [Related]
31. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease. Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738 [TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663 [TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. Parnetti L; Eusebi P; Lleó A Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974 [TBL] [Abstract][Full Text] [Related]
37. How many biomarkers to discriminate neurodegenerative dementia? Sancesario GM; Bernardini S Crit Rev Clin Lab Sci; 2015; 52(6):314-26. PubMed ID: 26292074 [TBL] [Abstract][Full Text] [Related]
38. A top-down proteomic approach reveals a salivary protein profile able to classify Parkinson's disease with respect to Alzheimer's disease patients and to healthy controls. Contini C; Fadda L; Lai G; Masala C; Olianas A; Castagnola M; Messana I; Iavarone F; Bizzarro A; Masullo C; Solla P; Defazio G; Manconi B; Diaz G; Cabras T Proteomics; 2024 Feb; 24(3-4):e2300202. PubMed ID: 37541286 [TBL] [Abstract][Full Text] [Related]
39. Biomarkers in Parkinson's disease (recent update). Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710 [TBL] [Abstract][Full Text] [Related]
40. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]